预约演示
更新于：2026-02-28
Clindamycin Phosphate
克林霉素磷酸酯
更新于：2026-02-28
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1972-10-02), |
最高研发阶段(中国)批准上市 |
特殊审评快速通道 (美国) |
登录后查看时间轴
结构/序列
分子式C18H34ClN2O8PS |
InChIKeyUFUVLHLTWXBHGZ-MGZQPHGTSA-N |
CAS号24729-96-2 |
关联
30
项与 克林霉素磷酸酯 相关的临床试验CTRI/2025/04/085538
Randomized Controlled Trial on Shalmali Transdermal Patch against Clindamycin gelin Acne vulgaris - NIL
NCT05867654
Oral Versus Intravenous Antibiotics for the Management of the Osteomyelitis of the Jaws: An Open-Label Non-Inferiority Single-Arm Clinical Trial
NCT06673641
A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group Study, Comparing Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Topical Gel 0.15%;3.1%;1.2% to CABTREO (Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide) Topical Gel and Both Active Treatments to a Placebo Control in the Treatment of Acne Vulgaris.
100 项与 克林霉素磷酸酯 相关的临床结果
登录后查看更多信息
100 项与 克林霉素磷酸酯 相关的转化医学
登录后查看更多信息
100 项与 克林霉素磷酸酯 相关的专利（医药）
登录后查看更多信息
577
项与 克林霉素磷酸酯 相关的文献（医药）2026-12-31JOURNAL OF DERMATOLOGICAL TREATMENT
Long-term efficacy and tolerability of clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% gel for acne: pooled results from two 6-month studies
Article
作者: Tanghetti, Emil A. ; Wroblewski, Karol ; Ghannoum, Mahmoud ; Harper, Julie C. ; Kircik, Leon H. ; Baldwin, Hilary ; Draelos, Zoe D. ; Gold, Linda Stein
AIM:
Given the chronic nature of acne, two 6-month studies were conducted to evaluate the long-term efficacy and tolerability of clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide (BPO) 3.1% gel (CAB)-the only approved triple-combination acne topical-and its effects on scarring/dyspigmentation in participants with moderate to severe acne.
MATERIALS AND METHODS:
Data were pooled from 2 identical, open-label, single-center studies conducted in participants (N = 50) aged ≥12 years with Investigator's Global Assessment (IGA) score of 3/4. Endpoints included change from baseline in IGA score, inflammatory/noninflammatory lesions, skin appearance (dryness, postinflammatory hyperpigmentation [PIH], postinflammatory erythema [PIE]), and scarring. Adverse events and tolerability (itching, burning, redness, swelling) were assessed.
RESULTS:
At week 24, 67% of participants achieved treatment success, and significant reductions from baseline in inflammatory (88%) and noninflammatory (68%) lesions were observed (p < 0.001, both). Significant reductions in scarring (33%), investigator- and participant-assessed PIH (71%; 78%, respectively), and PIE (77%; 77%, respectively) were demonstrated (p < 0.001, all). Most participants (>70%) reported no tolerability issues throughout the studies. Seven adverse events occurred; 4 were related to CAB, and 3 led to study discontinuation (BPO allergy [n = 2], irritant contact dermatitis to BPO [n = 1]).
CONCLUSIONS:
These findings suggest that CAB is an appropriate and effective topical option for the long-term treatment of acne vulgaris.
2025-12-31JOURNAL OF DERMATOLOGICAL TREATMENT
Efficacy and safety of fixed-dose clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% gel in Hispanic participants with moderate-to-severe acne: a pooled analysis
Article
作者: Callender, Valerie D. ; Cook-Bolden, Fran E. ; Alexis, Andrew F. ; Guenin, Eric ; Gold, Linda Stein ; Baldwin, Hilary
INTRODUCTION:
Clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% (CAB) gel is the only fixed-dose, triple-combination approved for acne. In phase 2 and 3 studies, CAB demonstrated superior efficacy to vehicle and component dyads. This post hoc analysis examined efficacy/tolerability of CAB in 147 self-identified Hispanic/Latino participants (referred to as Hispanic).
METHODS:
Data were pooled from one phase 2 (NCT03170388) and two phase 3 (NCT04214652, NCT04214639) double-blind, 12-week studies. Eligible participants aged ≥9 years with moderate to severe acne were randomized to once-daily CAB or vehicle. Endpoints included ≥2-grade reduction from baseline in Evaluator's Global Severity Score with clear/almost clear skin (treatment success) and inflammatory/noninflammatory lesion counts. Treatment-emergent adverse events (TEAEs) were assessed.
RESULTS:
At week 12, 56.2% of CAB-treated participants achieved treatment success vs 18.4% with vehicle (p < 0.001). Reductions in inflammatory/noninflammatory lesions were 77.1%/76.2% with CAB vs 56.4%/45.0% with vehicle, respectively (p < 0.001, all). CAB TEAE rates were similar to overall study populations (27.0% vs 24.6%-36.2%). Baseline hyperpigmentation scores decreased from 0.6 to 0.3 (1 = mild) at week 12 with CAB. CAB gel was efficacious, safe, and well tolerated in Hispanic participants. Limitations include lack of Fitzpatrick skin phototype and short study duration.
CONCLUSIONS:
This study provides support for acne treatment with CAB in ethnically diverse populations.
2025-12-01Journal of Drugs in Dermatology
Clindamycin Phosphate 1.2%/Adapalene 0.15%/ Benzoyl Peroxide 3.1% Gel for Moderate-to-Severe Acne: A Pooled Analysis by Age
Article
作者: Tanghetti, Emil A. ; Woolery-Lloyd, Heather C. ; Guenin, Eric ; Draelos, Zoe D. ; Kircik, Leon H. ; Harper, Julie C. ; Baldwin, Hilary ; Eichenfield, Lawrence F. ; Graber, Emmy
BACKGROUND:
Acne pathophysiology and presentation may differ between pediatric/adolescent/young adult (9-24 years) and adult (≥25 years) patients. Fixed-dose clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% (CAB) gel demonstrated superior efficacy to vehicle and component dyads with good safety/tolerability in 3 clinical trials of acne. This post hoc analysis evaluated the efficacy/safety of CAB in pediatric/adolescent/young adult ("younger") vs adult participants.
METHODS:
In one phase 2 (NCT03170388) and two phase 3 (NCT04214652, NCT04214639) trials, participants aged greater than or equal to 9 years with moderate-to-severe acne were randomized to once-daily CAB or vehicle gel. Pooled data were analyzed for participants grouped by age: younger (9-24 years; n=515) and adult (greater than or equal to 25 years; n=142). Endpoints included the percentage of participants achieving treatment success (greater than or equal to 2-grade reduction from baseline in Evaluator's Global Severity Score and clear/almost clear skin) and least squares mean percent change from baseline in inflammatory/noninflammatory lesions at week 12. Treatment-emergent adverse events (TEAEs) were evaluated throughout.
RESULTS:
At week 12, approximately half of CAB-treated participants in both age groups achieved treatment success (9-24: 50.6%; greater than or equal to 25: 49.0%) vs less than one-fourth with vehicle (15.7%; 20.6%; P<0.01, both). Across groups, CAB yielded >70% reductions in inflammatory/noninflammatory lesions vs 45% to 62% with vehicle (P≤0.001, all). For all endpoints, CAB efficacy was similar across age groups. Most TEAEs with CAB were of mild-to-moderate severity, and there were no age-related trends in safety/tolerability.
CONCLUSIONS:
Fixed-dose, triple-combination CAB gel was efficacious and well tolerated in participants with moderate-to-severe acne, regardless of age. Approximately half of the participants achieved clear/almost clear skin, with >70% reductions in lesion counts.
237
项与 克林霉素磷酸酯 相关的新闻（医药）2026-02-28
申请上市疫苗
2026-02-13
100 项与 克林霉素磷酸酯 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 腹腔脓肿 | 美国 | 2026-02-12 | |
| 脓胸 | 美国 | 2026-02-12 | |
| 子宫内膜炎 | 美国 | 2026-02-12 | |
| 感染性阴道炎 | 美国 | 2026-02-12 | |
| 肺脓肿 | 美国 | 2026-02-12 | |
| 骨髓炎 | 美国 | 2026-02-12 | |
| 腹膜炎 | 美国 | 2026-02-12 | |
| 输卵管-卵巢脓肿 | 美国 | 2026-02-12 | |
| 厌氧菌感染 | 美国 | 2017-04-20 | |
| 骨和关节感染 | 美国 | 2017-04-20 | |
| 妇科感染 | 美国 | 2017-04-20 | |
| 下呼吸道感染 | 美国 | 2017-04-20 | |
| 脓毒症 | 美国 | 2017-04-20 | |
| 皮肤和皮肤结构感染 | 美国 | 2017-04-20 | |
| 脓疱性痤疮 | 日本 | 2002-07-05 | |
| 细菌性阴道炎 | 美国 | 1992-08-11 | |
| 急性支气管炎 | 日本 | 1991-10-04 | |
| 出血性败血症 | 日本 | 1991-10-04 | |
| 喉炎 | 日本 | 1991-10-04 | |
| 中耳炎 | 日本 | 1991-10-04 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 307 | DARE-BV1clindamycin phosphate (Clindamycin Phosphate Vaginal Gel, 2%) | 夢網製窪獵鑰淵範願築 = 獵製築壓窪觸遞範鑰糧 築網願積夢鏇膚鏇顧願 (範範獵鹽觸鬱構糧網製, 顧醖艱獵蓋獵齋構艱醖 ~ 淵顧構襯艱蓋襯鬱醖鹽) 更多 | - | 2021-07-02 | ||
DARE-BV1clindamycin phosphate (Placebo Vaginal Gel (Universal HEC Placebo Gel)) | 夢網製窪獵鑰淵範願築 = 繭窪窪艱鏇醖憲窪餘獵 築網願積夢鏇膚鏇顧願 (範範獵鹽觸鬱構糧網製, 鏇廠餘築艱淵築醖鏇鹹 ~ 鹹夢顧鹹願顧築夢壓鹹) 更多 | ||||||
临床3期 | 1,236 | (Test Product) | 衊獵繭衊艱簾艱艱夢憲(夢廠壓願鑰醖鑰衊繭鹹) = 憲範艱衊夢顧鏇壓窪遞 鹹醖鹽艱廠築製築齋遞 (顧壓糧範鏇鏇醖膚襯選, 36.10) 更多 | - | 2021-05-04 | ||
(Reference Product) | 衊獵繭衊艱簾艱艱夢憲(夢廠壓願鑰醖鑰衊繭鹹) = 糧願廠齋窪齋鏇鏇網鬱 鹹醖鹽艱廠築製築齋遞 (顧壓糧範鏇鏇醖膚襯選, 36.83) 更多 | ||||||
临床3期 | 307 | 鹽簾醖顧構觸築鑰範鏇(淵構蓋顧醖醖窪窪範繭) = 廠蓋憲構齋醖糧積顧餘 獵繭鏇鏇壓蓋積艱醖艱 (獵願餘築夢繭觸遞鏇淵 ) 更多 | 积极 | 2020-12-07 | |||
Placebo | 鹽簾醖顧構觸築鑰範鏇(淵構蓋顧醖醖窪窪範繭) = 範膚艱淵獵製窪餘餘鹽 獵繭鏇鏇壓蓋積艱醖艱 (獵願餘築夢繭觸遞鏇淵 ) 更多 | ||||||
临床2期 | 591 | (Benzoyl Peroxide/Clindamycin + Tazarotene) | 獵餘窪鬱膚鏇醖齋齋鬱(築製範窪憲選憲積膚壓) = 醖顧觸鏇觸鹹淵積齋廠 網積簾鑰夢範艱簾網蓋 (繭鬱遞醖顧觸壓夢鏇鑰, 14.35) 更多 | - | 2017-03-06 | ||
Clindamycin+Benzoyl Peroxide (Benzoyl Peroxide/Clindamycin + Vehicle Cream) | 獵餘窪鬱膚鏇醖齋齋鬱(築製範窪憲選憲積膚壓) = 製鏇衊構衊膚壓鹹製構 網積簾鑰夢範艱簾網蓋 (繭鬱遞醖顧觸壓夢鏇鑰, 14.45) 更多 | ||||||
临床3期 | 1,018 | (Duac Once Daily Gel) | 顧淵憲觸淵網網顧鑰製(繭簾願繭積鏇獵簾築願) = 繭膚顧廠繭鏇廠鑰醖糧 積選鬱築鬱範築鑰蓋艱 (憲蓋襯顧網窪鑰醖獵醖, 1.05) 更多 | - | 2014-11-25 | ||
(Dalin Gel) | 顧淵憲觸淵網網顧鑰製(繭簾願繭積鏇獵簾築願) = 憲膚憲憲構衊獵範鏇窪 積選鬱築鬱範築鑰蓋艱 (憲蓋襯顧網窪鑰醖獵醖, 1.03) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用